William Mack & Associates
MRNA icon

William Mack & Associates’s Moderna MRNA Stock Holding History

William Mack & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.62K Buy
+24
New +$2.59K ﹤0.01% 461

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $2.62B AUM 125.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

William Mack & Associates's MRNA Position: Q3 2026 in Review

William Mack & Associates opened a new position in Moderna (MRNA) in Q3 2026: 24 shares worth $4.62K. The stake represents ﹤0.01% of the portfolio and ranks #461 among its holdings.

858 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • William Mack & Associates held 24 shares of Moderna worth $4.62K as of Q3 2026.
  • Moderna was a new William Mack & Associates position in Q3 2026.
  • Moderna made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #461 holding.
  • 858 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.